ClearPoint Neuro (CLPT) CBO settles RSUs, 15,151 shares for taxes

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall settled restricted stock units into common shares as part of scheduled vesting. Each unit converts into one share of common stock, and this transaction reflects the routine exercise or conversion of 30,995 restricted stock units.

In connection with the vesting, 15,151 shares of common stock were delivered back to ClearPoint Neuro at $11.53 per share to satisfy tax withholding obligations, rather than being sold in the open market. After these transactions, Stigall directly holds 108,482 shares of common stock.

Insider Trade Summary

30,995 shares exercised/converted

Mixed 3 txns

Insider STIGALL L. JEREMY

Role Chief Business Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	30,995	$0.00	--
Exercise	Common Stock	30,995	$0.00	--
Tax Withholding	Common Stock	15,151	$11.53	$175K

Holdings After Transaction: Restricted Stock Units — 30,995 shares (Direct); Common Stock — 123,633 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STIGALL L. JEREMY

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		M		30,995	A	(1)	123,633	D
Common Stock	03/12/2026		F		15,151(2)	D	$11.53	108,482	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/12/2026		M			30,995	(1)	(1)	Common Stock	30,995	(1)	30,995	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

	/s/ Danilo D'Alessandro, by Power of Attorney for Jeremy L. Stigall	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report for L. Jeremy Stigall?

ClearPoint Neuro reported that Chief Business Officer L. Jeremy Stigall settled 30,995 restricted stock units into common shares on their scheduled vesting date, a routine compensation-related event with no open-market share purchases or sales disclosed.

How many ClearPoint Neuro (CLPT) shares were used for tax withholding in this Form 4?

The filing shows 15,151 shares of ClearPoint Neuro common stock were delivered to the company at $11.53 per share to cover tax withholding obligations tied to the vesting of restricted stock units, rather than being sold on the open market.

Did the ClearPoint Neuro (CLPT) insider exercise options or restricted stock units?

The insider exercised or converted 30,995 restricted stock units, each representing a right to receive one share of ClearPoint Neuro common stock. This settlement occurred on the scheduled vesting date, consistent with the company’s equity compensation arrangements for executives.

How many ClearPoint Neuro (CLPT) shares does L. Jeremy Stigall own after this transaction?

Following the settlement of restricted stock units and related tax withholding, Chief Business Officer L. Jeremy Stigall directly holds 108,482 shares of ClearPoint Neuro common stock, according to the post-transaction ownership figure disclosed in the Form 4.

Was there an open-market sale or purchase of ClearPoint Neuro (CLPT) shares in this Form 4?

The Form 4 reports no open-market purchases or sales. Shares were acquired through settlement of restricted stock units and a portion, 15,151 shares, was delivered back to ClearPoint Neuro solely to satisfy tax withholding obligations associated with the vesting event.